Title |
HPV Update: Vaccination, Screening, and Associated Disease
|
---|---|
Published in |
Journal of General Internal Medicine, May 2016
|
DOI | 10.1007/s11606-016-3725-z |
Pubmed ID | |
Authors |
Megan McNamara, Pelin Batur, Judith M. E. Walsh, Kay M. Johnson |
Abstract |
Human papillomavirus (HPV) infection is the causative agent in cervical cancer, and is associated with numerous other genital cancers, including vulvar, vaginal, and anal cancer. Primary prevention with HPV vaccination is safe and efficacious, and a recently approved HPV vaccine will provide even more extensive protection against several oncogenic HPV strains. Screening strategies for HPV are rapidly evolving, reflecting the essential role that HPV infection plays in cervical cancer. This article highlights new evidence regarding the efficacy of the recently approved 9-valent HPV (9vHPV) vaccine and the use of primary high-risk HPV testing in cervical cancer screening. We consider the utility of urinary HPV testing in routine clinical practice and review current guidelines regarding anal HPV screening. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 33% |
Spain | 2 | 33% |
France | 1 | 17% |
Unknown | 1 | 17% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 67% |
Scientists | 1 | 17% |
Science communicators (journalists, bloggers, editors) | 1 | 17% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 101 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 20 | 20% |
Student > Bachelor | 15 | 15% |
Student > Doctoral Student | 10 | 10% |
Student > Ph. D. Student | 8 | 8% |
Other | 7 | 7% |
Other | 13 | 13% |
Unknown | 28 | 28% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 36 | 36% |
Nursing and Health Professions | 10 | 10% |
Biochemistry, Genetics and Molecular Biology | 9 | 9% |
Social Sciences | 4 | 4% |
Computer Science | 2 | 2% |
Other | 7 | 7% |
Unknown | 33 | 33% |